CLOs on the Move

PuraCap

www.puracap.com

 
EpiCeram® Controlled Release Skin Barrier Emulsion is a leading prescription product that has the ability to help repair and heal the skin barrier through a unique mode-of-action different from other medications and eczema treatments. Only EpiCeram® co...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Qosina

Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.

Harmony Business Supplies Inc

Harmony Business Supplies Inc is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mitchell and Resnikoff

Mitchell & Resnikoff is a Elkins Park, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.